- Home
- WPP vs PTCT Comparison
WPP vs PTCT Comparison
Compare WPP & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WPP | PTCT |
|---|---|---|
| Founded | 1985 | 1998 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 6.1B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | WPP | PTCT |
|---|---|---|
| Price | $21.25 | $72.73 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 17 |
| Target Price | N/A | ★ $73.76 |
| AVG Volume (30 Days) | 472.6K | ★ 1.3M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | ★ 9.98% | N/A |
| EPS Growth | ★ 86.47 | N/A |
| EPS | 0.47 | ★ 8.94 |
| Revenue | ★ $19,423,208,660.00 | $1,779,150,000.00 |
| Revenue This Year | N/A | $129.80 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.68 | ★ $8.11 |
| Revenue Growth | N/A | ★ 97.54 |
| 52 Week Low | $17.47 | $35.95 |
| 52 Week High | $49.12 | $87.50 |
Technical Indicators
Market Signals| Indicator | WPP | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 42.79 | 38.43 |
| Support Level | $21.50 | $73.32 |
| Resistance Level | $23.79 | $77.87 |
| Average True Range (ATR) | 0.69 | 3.02 |
| MACD | -0.26 | -0.43 |
| Stochastic Oscillator | 5.77 | 17.88 |
Price Performance
Historical ComparisonAbout WPP WPP plc
Headquartered in the United Kingdom, WPP is the world's largest ad holding company based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe. WPP is the largest media buying entity in the world.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.